Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/26
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease TranscriptSeeking Alpha • 05/01/26
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewsWire • 05/01/26
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's DiseaseGlobeNewsWire • 04/30/26
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool • 03/25/26
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock GainThe Motley Fool • 03/18/26
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?Zacks Investment Research • 03/13/26
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/13/26
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA DecisionThe Motley Fool • 03/09/26
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity SalesZacks Investment Research • 02/24/26
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be OvervaluedSeeking Alpha • 02/23/26
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/23/26
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/23/26